CONNECT BIOPHARMA HOLDINGS L (CNTB) Stock News
NASDAQ:CNTB - Nasdaq - US2075231017 - ADR - Currency: USD
CNTB Latest News, Press Relases and Analysis
Tuesday's after hours session: top gainers and losers
As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference
Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference
– Data to be presented supports development of rademikibart for patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation – –...
Bullfrog AI and Connect Biopharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Mentions: BFRG
Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart
Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart
– FDA aligned on plan to initiate parallel Phase 2 trials of rademikibart in patients with moderate-to-severe asthma or COPD experiencing an acute...
Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma
Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma
– Rademikibart demonstrated rapid onset of action with significant improvements in lung function observed at one week and maintained through 24 weeks – –...
Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update
Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update
Strengthened leadership team with key appointments, including Barry Quart, Pharm.D. as CEO, and David Szekeres as President, bringing deep clinical,...
Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a clinical-stage...
Connect Biopharma to Present at Two Upcoming Investor Conferences
Attovia Therapeutics Appoints Chief Financial Officer
Steven Chan, an accomplished finance leader, joins Attovia as Chief Financial Officer
Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024
Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
Announced new U.S.-based leadership with the appointment of Barry Quart, Pharm.D. as Chief Executive Officer (CEO) and David Szekeres as PresidentConnect’s...
Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
SAN DIEGO, CA and TIACANG, China, July 01, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a...
Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a...
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
Mentions: GRI
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
Industry leader Barry Quart, Pharm.D. appointed as Chief Executive Officer succeeding Zheng Wei, Ph.D., who will remain on the Board of Directors and serve...
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
Rademikibart treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and sustained through Week...
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
SAN DIEGO, CA and TAICANG, China, May 07, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the...
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
Reported two positive readouts for rademikibart, the Company’s lead asset, from the Global Phase 2b trial in moderate-to-severe persistent asthma and from...
Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
SAN DIEGO and TAICANG, China, March 19, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the...
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
James Huang brings over 30 years of biotech experience as a successful entrepreneur, investor and key opinion leader in the healthcare sector SAN DIEGO,...